Skip to main content

Table 1 Patient characteristics and MK-1775 sensitivity for primary AML patient samples

From: CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells

Patient Gender Age (year) Disease status FAB subtype WBC (×103/μL) Blast purity (%) Cytogenetics MK-1775 IC50(nM)
AML#0 Female 13 At diagnosis M2 39.9 79 46, XX, t(8;21)(q22;q22) 5996.5
AML#1 Female 50 At diagnosis M4 22.66 52 46, XX, del(5q), add(12p) 2448.5
AML#2 Male 20 At diagnosis M2 23.55 42 45, X, -Y, t(8;21)(q22;q22) 3204.0
AML#3 Male 4 At diagnosis M3 4.71 75 46, XY, t(15;17)(q22;q21) 461.0
AML#4 Male 55 At relapse M2 5.64 14 46, XY, t(8;21)(q22;q22) 844.0
AML#5 Female 57 At relapse M2 22.16 70 46, XX 948.3
AML#6 Male 60 At diagnosis M3 1.83 86 46, XY, t(15;17)(q22;q21) 233.7
AML#7 Female 53 At relapse M4 3.87 36 46, XX 325.0
AML#8 Male 55 At diagnosis M2 3.87 32 46, XY 887.9
AML#9 Female 35 At relapse M5 17.71 87 47, XX, +10, t(16;21)(p11;q22), add(11p) 744.4
AML#10 Male 23 At diagnosis M2 25.89 53 46, XY, del(9q) 439.7
AML#11 Female 43 At diagnosis M2 25.12 91 46, XX 411.3
AML#12 Male 6 At diagnosis M3 93.99 85 46, XY, t(15;17)(q22;q21) 277.5
AML#13 Male 52 At diagnosis M2 1.65 27 46, XY, t(11;15;17)(q25;q15;q21) 3579.5
AML#14 Female 18 At diagnosis M3 1.62 64 46, XX 9113
AML#15 Female 63 At diagnosis M2 0.6 23 46, XX 344.1
AML#16 Male 38 At diagnosis M3 2.27 90 46, XY, t(15;17)(q22;q21) 216.9
AML#17 Female 45 At diagnosis M4 1.52 36 46, XX 3473.0
AML#18 Female 19 At relapse M2 21.55 52 46, XX, t(8;21)(q22;q22) 1187.0
AML#19 Male 4 At diagnosis M4 77.32 41 46, XY 5587.0
AML#21 Male 42 At diagnosis M4 10.60 51 46, XY/44, XY, -17, -19, (11q-?) 1176.0
AML#22 Female 47 At diagnosis M5 244.53 80 46, XX 1255.0
AML#23 Male 60 At diagnosis M5 2.10 81 46, XY, +2, +8, I(12)(q10) 1480.0
AML#25 Female 12 At diagnosis M3 5.11 88 46, XX, t(15;17)(q22;q21) 615.1
AML#26 Male 59 At diagnosis M2 129.98 81 46, XY 5868.0
AML#27 Female 41 At relapse M4 40.20 24 47, XX,del(5q),+8,t(15;18)(q12,q23) 6384.0
AML#29 Male 9 At diagnosis M4 68.14 31 46, XY, t(6;9)(p22;q34) 880.4
AML#31 Male 17 At diagnosis M2 12.94 69 46, XY 453.7
AML#32 Female 76 At diagnosis M5 13.93 85 46, XX 2888.0